Our top pick for
ModivCare Inc is a medical care facilities business based in the US. ModivCare shares (MODV) are listed on the NASDAQ and all prices are listed in US Dollars. ModivCare employs 3,800 staff and has a trailing 12-month revenue of around USD$1.4 billion.
|52-week range||USD$40.4 - USD$184.71|
|50-day moving average||USD$165.0547|
|200-day moving average||USD$125.0474|
|Wall St. target price||USD$176.25|
|Dividend yield||N/A (2.38%)|
|Earnings per share (TTM)||USD$2.096|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing ModivCare stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ModivCare's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
ModivCare's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 74x. In other words, ModivCare shares trade at around 74x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
ModivCare's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.7596. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into ModivCare's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
ModivCare's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$131.3 million.
The EBITDA is a measure of a ModivCare's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$1.4 billion|
|Operating margin TTM||8.14%|
|Gross profit TTM||USD$108.8 million|
|Return on assets TTM||9.77%|
|Return on equity TTM||20.1%|
|Market capitalisation||USD$2.1 billion|
TTM: trailing 12 months
There are currently 416,338 ModivCare shares held short by investors – that's known as ModivCare's "short interest". This figure is 10.6% up from 376,292 last month.
There are a few different ways that this level of interest in shorting ModivCare shares can be evaluated.
ModivCare's "short interest ratio" (SIR) is the quantity of ModivCare shares currently shorted divided by the average quantity of ModivCare shares traded daily (recently around 83101.397205589). ModivCare's SIR currently stands at 5.01. In other words for every 100,000 ModivCare shares traded daily on the market, roughly 5010 shares are currently held short.
However ModivCare's short interest can also be evaluated against the total number of ModivCare shares, or, against the total number of tradable ModivCare shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ModivCare's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 ModivCare shares in existence, roughly 30 shares are currently held short) or 0.0359% of the tradable shares (for every 100,000 tradable ModivCare shares, roughly 36 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against ModivCare.
Find out more about how you can short ModivCare stock.
Dividend payout ratio: 23.64% of net profits
Recently ModivCare has paid out, on average, around 23.64% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.38% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), ModivCare shareholders could enjoy a 2.38% return on their shares, in the form of dividend payments. In ModivCare's case, that would currently equate to about $N/A per share.
While ModivCare's payout ratio might seem low, this can signify that ModivCare is investing more in its future growth.
Over the last 12 months, ModivCare's shares have ranged in value from as little as $40.4 up to $184.71. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ModivCare's is 0.6692. This would suggest that ModivCare's shares are less volatile than average (for this exchange).
ModivCare Inc., a technology-enabled healthcare services company, provides a suite of integrated supportive care solutions for public and private payors and patients. It offers non-emergency medical transportation services for Medicaid or Medicare eligible members, whose limited mobility or financial resources hinder their ability to access necessary healthcare and social services. The company also provides in-home care optimization services, including comprehensive health assessments through a network of community-based clinicians and a fleet of mobile health clinics. The company was formerly known as The Providence Service Corporation and changed its name to ModivCare Inc. in January 2021.The company was founded in 1996 and is headquartered in Denver, Colorado.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.